FRI0280 Efficacy and Safety of Tocilizumab as First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study (Tenor)

V. Devauchelle (1, 2) , J.-M. Berthelot (3) , D. Cornec (2, 1) , Y. Renaudineau (4, 2) , T. Marhadour (2) , S. Jousse-Joulin (2, 1) , S. Querellou (5) , F. Guarrigues , M. de Bandt (6) , M. Gouillou (7) , A. Saraux (2, 1)

1 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie
2 EA2216 - Immunologie et Pathologie
3 Service de rhumatologie [Nantes]
4 Laboratoire d'Immunologie et Immunothérapie
5 Department of Nuclear Medicine
6 Service de rhumatologie
7 CIC - Brest - Centre d'Investigation Clinique

Domaines: Immunologie

V. Devauchelle, J.-M. Berthelot, D. Cornec, Y. Renaudineau, T. Marhadour, et al.. FRI0280 Efficacy and Safety of Tocilizumab as First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study (Tenor). Annual European Congress of Rheumatology, Jun 2015, Rome, Italy. ⟨10.1136/annrheumdis-2015-eular.2727⟩. ⟨hal-01183307⟩